Monoamine oxidase inhibitors MAOIs

Urate oxidase rDNA

Selective monoamine oxidase type B MAOB inhibitors

The clinical benefit of monoamine oxidase type B (MAO-B) inhibitors is thought to arise from an ability of these medications to enhance the level of dopamine by decreasing the catabolism. Additional...

ACE inhibitors

Phosphodiesterase 4 PDE 4 Inhibitors

Phosphodiesterase 4 (PDE-4) inhibitors have attracted considerable interest as potential therapeutic agents for diseases including chronic obstructive pulmonary disease. PDE-4 inhibitors are known to...

Cardiomyocyte-specific transgenic expression of lysyl oxidase-like protein-1 induces cardiac hypertrophy in mice

EC approves Krystexxa pegloticase

The European Commission approved Krystexxa pegloticase from Savient Pharmaceuticals Inc. (NASDAQ:SVNT) to treat severe chronic tophaceous gout in adult patients. The drug is indicated in patients who...

Pharmaxis Gets Negative Recommendation From U.S. FDA Advisory Panel

Australia's Pharmaxis had a setback when U.S. FDA advisors recommended rejection of its Bronchitol (manitol) for treating cystic fibrosis in persons over six years of age.

US FDA calls for new trial with Pharmaxis' CF drug Bronchitol

Australian pharma company Pharmaxis (ASX: PXS) says it has received a complete response letter from the Food and Drug Administration confirming Bronchitol (mannitol dry powder for inhalation) cannot y...

Panel rebuffs Pharmaxis' Bronchitol for CF

FDA's Pulmonary-Allergy Drugs Advisory Committee voted 14-0 against approval of an NDA for Bronchitol mannitol from Pharmaxis Ltd. (ASX:PXS; Pink:PXSLY) to improve pulmonary function in cystic fibrosi...

Pharmaxis receives Bronchitol complete response

Pharmaxis Ltd. (ASX:PXS; Pink:PXSLY) received a complete response letter from FDA for an NDA for Bronchitol mannitol to improve pulmonary function in cystic fibrosis (CF) patients six years of age and...

Pharmaxis cuts 30% of jobs following FDA's Bronchitol rejection

Pharmaxis said it will cut expenses by 29% and reduce its employee headcount by 30% two months after the US FDA rejected the Australian company's dry-powder mannitol medicine developed to improve pu...

A Link Between Tissue Scarring And Cancer Metastasis

What to fear most if faced by a cancer diagnosis is the spread of the cancer to other parts of the body. This process called metastasis accounts for over 90% of cancer patient deaths and therefore is...

Identification of the disulfide bonds of lysyl oxidase.

Proteolytic digestion of bovine aortic lysyl oxidase followed by tandem mass spectrometry has enabled assignment of all five disulfide bonds. The results indicate that the enzyme has a very stable cen...

Expression of matrix metalloproteinases, their inhibitors, and lysyl oxidase in myocardial samples from dogs with end-stage systemic and cardiac diseases.

Objective-To compare the degree of mRNA expression for matrix metalloproteinases (MMPs), tissue inhibitors (TIMPs), and lysyl oxidase in myocardial samples from dogs with cardiac and systemic diseases...

Lysyl Oxidase-like-2 (LOXL2) Is a Major Isoform in Chondrocytes and Is Critically Required for Differentiation.

The lysyl oxidase family is made up of five members: lysyl oxidase (LOX) and lysyl oxidase-like 1-4 (LOXL1-LOXL4). All members share conserved C-terminal catalytic domains that provide for lysyl oxida...

Lysyl oxidase: A lung adenocarcinoma biomarker of invasion and survival.

Lung adenocarcinoma invasion and metastasis arises from autocrine and paracrine signaling events between tumor epithelial cells and the stromal microenvironment that is mediated in part by transformin...

Inhibition of mammary tumor growth using lysyl oxidase-targeting nanoparticles to modify extracellular matrix.

A cancer nanotherapeutic has been developed that targets the extracellular matrix (ECM)-modifying enzyme Lysyl Oxidase (LOX) and alters ECM structure. PLGA nanoparticles (~220 nm) coated with a LOX in...